Presentations Chinese Forum

  Session 1: Introduction to Integrase Inhibitors
 
HIV integrase Inhibitors: A novel mechanisms of action
Dr. H. Wu, Beijing You’an Hospital, Beijing, China
 
Resistance Characteristics of different Integrase Inhibitors - Chinese version
Resistance Characteristics of different Integrase Inhibitors - English version
Dr. C. Boucher, Erasmus Medical Center, The Netherlands
 


The role of Integrase Inhibitors in International Treatment Guidelines (coming soon)
Prestentation of: Dr. M. Boyd, University of Adelaide, Australia
Presentented by: Dr. C. Boucher, Erasmus Medical Center, The Netherlands

 Abstract-driven presentation
 Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Treatment-Naïve Asian Adults: Week 144 results
Tina Zheng, Gilead, China
 Session 2: Optimal Use of Integrase Inhibitors in the Clinic
 


Optimal use of integrase inhibitors in routine clinical practice - Chinese version
Optimal use of integrase inhibitors in routine clinical practice - English version
Dr. K. Brinkman, Onze Lieve Vrouwe Gasthuis, the Netherlands

 
Taiwan’s Experiences with Integrase Inhibitors
Dr. C.C. Hung, National Taiwan University Hospital, Taiwan
 Abstract-driven presentation
 Efficacy and Safety of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir alafenamide (E/C/F/TAF) in Virologically Suppressed Asian Adults with Renal Impairment: 144 Week
Ning Li, Gilead, China
 Session 3: The use of Integrase Inhibitors in Special Populations
 
HIV - Hepatitis Co-infected patient (not available)
Dr. W. Cai, Guangzhou Medical University, China
 
Long-term HIV treatment: The Importance of Initial Antiretroviral Regimen Selection
Dr. H. Zhao, Beijing Ditan Hospital, Capital Medical University, China